Amprologix key facts
as of Oct 2026- Developer of antimicrobial-resistant drugs designed to combat drug-resistant infections.
- Amprologix is valued at approximately $10.9M as of Oct 2026 (last reported valuation).
- It has raised $1.0M.
- Notable investors include MassChallenge, UK Research and Innovation, Plutus Investment Group, Ingenza, University of Plymouth.
- Status: Privately Held (backing).
Amprologix's last reported valuation, Oct 2025. Nothing priced has surfaced since.
- ·Watch Amprologix: the Monday email on marks, rounds and moves
Amprologix funding rounds
No funding rounds for Amprologix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Amprologix valuation
Amprologix's last reported valuation was $10.9 million in Oct 2025. No priced round, secondary trade or fund mark has surfaced since.
Amprologix investors
5 investors are on record for Amprologix, including MassChallenge, UK Research and Innovation, Plutus Investment Group and Ingenza.
About Amprologix
Developer of antimicrobial-resistant drugs designed to combat drug-resistant infections. The company utilizes cutting-edge machine learning algorithms to improve antibiotic properties, including nasal decolonization of methicillin-resistant Staphylococcus aureus, pneumonia, and surface skin infections, enabling clients to combat the growing problem of antibiotic resistance.
- Sector
- Healthcare
- HQ
- Plymouth, United Kingdom
- Founded
- 2018
- Employees
- 4
- Website
- amprologix.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.